E-PaperAstrazeneca Pharma India Q4 Results Live : profit rise by 128.61% YOY
Astrazeneca Pharma India Q4 Results Live : Revenue increased by 34.6% YoY & profit increased by 128.61% YoY
Astrazeneca Pharma India Q4 Results Live : Astrazeneca Pharma India declared their Q4 results on 27 May, 2024. The topline increased by 34.6% & the profit increased by 128.61% YoY. As compared to the previous quarter the revenue grew by 25.31% and the profit increased by 149.84%.
The Selling, general & administrative expenses declined by 9.02% q-o-q & increased by 2.77% Y-o-Y.
The operating income was up by 301.92% q-o-q & increased by 196.96% Y-o-Y.
The EPS is ₹15.79 for Q4 which decreased by 16.21% Y-o-Y.
Astrazeneca Pharma India has delivered 11.76% return in the last 1 week, 36.22% return in last 6 months and 16.94% YTD return.
Currently the Astrazeneca Pharma India has a market cap of ₹16157.5 Cr and 52wk high/low of ₹7220.95 & ₹3241.6 respectively.
Astrazeneca Pharma India Financials
| Period | Q4 | Q3 | Q-o-Q Growth | Q4 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 383.2 | 305.79 | +25.31% | 284.7 | +34.6% |
| Selling/ General/ Admin Expenses Total | 83.3 | 91.56 | -9.02% | 81.06 | +2.77% |
| Depreciation/ Amortization | 3.76 | 3.7 | +1.61% | 4.25 | -11.41% |
| Total Operating Expense | 337.57 | 294.44 | +14.65% | 269.34 | +25.33% |
| Operating Income | 45.63 | 11.35 | +301.92% | 15.36 | +196.96% |
| Net Income Before Taxes | 54.35 | 20.4 | +166.45% | 23.28 | +133.53% |
| Net Income | 39.48 | 15.8 | +149.84% | 17.27 | +128.61% |
| Diluted Normalized EPS | 15.79 | 6.32 | +149.84% | 18.84 | -16.21% |
- Top Gainers
- Top Losers
- 52 Week High
